tirzepatide and kidney issues function: an intriguing and promising observation Next-generation therapeutics for diabetic kidney

Description

Fact: Clinical studies show semaglutide can lead to an average weight loss of 15% or more of total body weight

Inform patients that blood glucose may be normal even in the presence of ketoacidosis

[DOI] [PubMed] [Google Scholar] 74.Barnett A.H., Mithal A., Manassie J., Jones R., Rattunde H., Woerle H.J., Broedl U.C., EMPA-REG RENAL Trial Investigators Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial

Misuse or self-medication, however, may lead to avoidable side effects and long-term health risks

Conclusion In summary, high-quality, RCT-based evidence has shown that semaglutide 2.4 mg is an effective weight management therapy in conjunction with lifestyle interventions for overweight and obesity in people with and without T2DM